200,000+ products from a single source!


Home > Amines > 137281-23-3


137281-23-3 | L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-

CAS No: 137281-23-3 Catalog No: AG00131R MDL No:MFCD19105065

Product Description

Catalog Number:
Chemical Name:
L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-
CAS Number:
Molecular Formula:
Molecular Weight:
MDL Number:
(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid
InChI Key:
NSC Number:


Compound Is Canonicalized:
Covalently-Bonded Unit Count:
Defined Atom Stereocenter Count:
Defined Bond Stereocenter Count:
Exact Mass:
Formal Charge:
Heavy Atom Count:
Hydrogen Bond Acceptor Count:
Hydrogen Bond Donor Count:
Isotope Atom Count:
Molecular Weight:
Monoisotopic Mass:
Rotatable Bond Count:
Topological Polar Surface Area:
Undefined Atom Stereocenter Count:
Undefined Bond Stereocenter Count:


Title Journal
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis. Chemical research in toxicology 20150518
Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. International journal of oncology 20140701
KRAS mutation status is associated with enhanced dependency on folate metabolism pathways in non-small cell lung cancer cells. Molecular cancer therapeutics 20140601
Pemetrexed downregulates ERCC1 expression and enhances cytotoxicity effected by resveratrol in human nonsmall cell lung cancer cells. Naunyn-Schmiedeberg's archives of pharmacology 20131201
Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer treatment reviews 20130501
Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology 20130101
Pemetrexed alters folate phenotype and inflammatory profile in EA.hy 926 cells grown under low-folate conditions. European journal of pharmacology 20121205
Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Current oncology (Toronto, Ont.) 20120601
Death receptor 5 and cellular FLICE-inhibitory protein regulate pemetrexed-induced apoptosis in human lung cancer cells. European journal of cancer (Oxford, England : 1990) 20111101
Establishment of pemetrexed-resistant non-small cell lung cancer cell lines. Cancer letters 20111028
Synthesis, biological, and antitumor activity of a highly potent 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate inhibitor with proton-coupled folate transporter and folate receptor selectivity over the reduced folate carrier that inhibits β-glycinamide ribonucleotide formyltransferase. Journal of medicinal chemistry 20111027
Medical treatment of mesothelioma: anything new? Current oncology reports 20110801
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung cancer (Amsterdam, Netherlands) 20110701
Phase II study of pemetrexed and cisplatin, with chest radiotherapy followed by docetaxel in patients with stage III non-small cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110501
Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 20110401
Targeted therapies and other agents as first-line maintenance and beyond: particular benefit in pulmonary adenocarcinoma patients. Current medicinal chemistry 20110101
ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer science 20101101
Pemetrexed in advanced non-small-cell lung cancer. Expert opinion on pharmacotherapy 20100601
Cancer chemotherapy: targeting folic acid synthesis. Cancer management and research 20100101
Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20091001
Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20090710
Valproate, in combination with pemetrexed and cisplatin, provides additional efficacy to the treatment of malignant mesothelioma. Clinical cancer research : an official journal of the American Association for Cancer Research 20090415
A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 20070615
Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. British journal of cancer 20070312
Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow. Anticancer research 20070101
[Pemetrexed: from preclinic to clinic]. Bulletin du cancer 20070101
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer chemotherapy and pharmacology 20060401
Pemetrexed-associated urticarial vasculitis. Lung cancer (Amsterdam, Netherlands) 20060201
The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Molecular cancer therapeutics 20060201
Pemetrexed: a multitargeted antifolate. Clinical therapeutics 20050901
Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer research 20050801
Cytotoxic effects of pemetrexed in gastric cancer cells. Cancer science 20050601
The multidrug resistance protein 5 (ABCC5) confers resistance to 5-fluorouracil and transports its monophosphorylated metabolites. Molecular cancer therapeutics 20050501
The roles of thymidylate synthase and p53 in regulating Fas-mediated apoptosis in response to antimetabolites. Clinical cancer research : an official journal of the American Association for Cancer Research 20040515
Accumulation of 5-phosphoribosyl-1-pyrophosphate in human CCRF-CEM leukaemia cells treated with antifolates. The international journal of biochemistry & cell biology 20040301
Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20031101
Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert review of anticancer therapy 20030401
Design, synthesis, and biological activities of classical N-[4-[2-(2-amino-4-ethylpyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-l-glutamic acid and its 6-methyl derivative as potential dual inhibitors of thymidylate synthase and dihydrofolate reductase and as potential antitumor agents. Journal of medicinal chemistry 20030213
Pemetrexed combination therapy in the treatment of non-small cell lung cancer. Seminars in oncology 20020401
A new route to 7-substituted derivatives of n-[4-(2-[2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimidin-5-yl]ethyl)benzoyl]-L-glutamic acid [ALIMTA (LY231514, MTA)]. The Journal of organic chemistry 20010601

Related Products

© 2019 Angene International Limited. All rights Reserved.